Canada
cell and gene therapy market is anticipated to witness impressive growth during
the forecast period. This can be ascribed to the development of a few modern competitors and the
expansion of item advancement capabilities due to the developing demand for
CMO/CDMO administrations across the region. Also, developing demand for
cutting-edge medicines is anticipated to drive the growth of Canada cell and
gene therapy market during the forecast period. Also, increase in outsourcing
the fabricating handle for cell and gene treatment is expected to create
lucrative growth of Canada cell and gene therapy market during the forecast
period. Similarly, the increasing demand for cancers and genetic disorders is
anticipated to restrain the growth of Canada cell and gene therapy market over the
years. In 2020, an estimated
225,800 Canadians are expected to be diagnosed with cancer. In 2020, around 191
out of 100,000 Canadians died from major cardiovascular diseases.
Supportive
Regulatory Environment can Influence the Growth of the Market
The supportive
regulatory environment in Canada has played a pivotal role in influencing the
growth of the cell and gene therapy market. The regulatory authority, Health
Canada has implemented measures to expedite the approval process for cell and
gene therapies. This includes the establishment of accelerated review pathways
and priority review designations for innovative therapies. These initiatives
aim to reduce the time it takes for therapies to reach patients, allowing
companies to bring their products to market more quickly. Health
Canada has adopted a risk-based approach to regulation, focusing on the
evaluation of the safety, quality, and efficacy of cell and gene therapies.
This approach considers the unique characteristics of these therapies and allows
for flexibility in the regulatory process. It encourages the development of
innovative treatments while ensuring patient safety and product quality. Health
Canada has taken steps to enhance collaboration with industry stakeholders,
researchers, and healthcare professionals. This collaboration allows for the
exchange of information, expertise, and best practices, facilitating a better
understanding of the regulatory requirements and expectations. It enables
proactive discussions during the development process, helping to address
regulatory challenges and optimize the pathway to approval. Health
technology assessment (HTA) agencies in Canada, such as the Canadian Agency for
Drugs and Technologies in Health (CADTH) work closely with regulatory
authorities to evaluate the value and cost-effectiveness of cell and gene
therapies. These assessments inform reimbursement decisions and ensure access
to these therapies. The integration of regulatory and reimbursement
considerations supports a more holistic approach to market access and adoption.
Research and Development
Opportunities Propel the Growth of the Market
Research and
development (R&D) efforts have played a crucial role in driving the growth
of the cell and gene therapy market in Canada. R&D activities have led
to significant scientific advancements in the field of cell and gene therapies.
Researchers in Canada have made notable contributions to understanding the
underlying mechanisms of diseases, identifying potential therapeutic targets, and
developing innovative treatment approaches. These advancements have laid the
foundation for the development of novel cell and gene therapies with the
potential to address unmet medical needs. R&D efforts have resulted
in the development of new cell and gene therapies in Canada. Researchers and
biotechnology companies have collaborated to translate scientific discoveries
into potential treatment options for various diseases and conditions. Through
preclinical and clinical studies, these therapies are evaluated for safety and
efficacy, paving the way for their eventual approval and commercialization. R&D
efforts have facilitated to conduct clinical trials in Canada, which are
essential for demonstrating the safety and efficacy of cell and gene therapies.
Clinical trials provide evidence to support regulatory approvals, reimbursement
decisions, and adoption by healthcare providers. The availability of robust
clinical trial infrastructure, including specialized research centers and
hospitals, has enabled the efficient execution of these trials, generated
valuable data and advanced the understanding of these therapies. R&D
activities have led to the development of intellectual property, including
patents and proprietary technologies. Protecting intellectual property is
crucial for attracting investment and incentivizing further R&D efforts.
The presence of strong intellectual property protection in Canada has provided
assurance to companies and researchers, encouraging them to invest in the
development and commercialization of cell and gene therapies.
Download Free Sample Report
Growing Collaborations
and Partnerships will Further Drive the Growth of the Market
Collaborations
and partnerships have a significant influence on the growth of the cell and
gene therapy market in Canada. They foster synergies, enhance knowledge
sharing, and facilitate resource pooling, contributing to the advancement and
commercialization of innovative therapies. Collaborations and
partnerships bring together, the diverse expertise from academia, industry, and
government organizations. These collaborations facilitate the exchange of
knowledge, research findings, and technical knowledge. By pooling resources and
expertise, researchers and companies can accelerate the pace of discovery,
conduct more comprehensive studies, and advance the development of cell and
gene therapies. Collaborative R&D efforts can lead to breakthroughs in
understanding disease mechanisms, identifying therapeutic targets, and
optimizing treatment approaches. Collaborative partnerships
can help leverage existing infrastructure and facilities to support cell and
gene therapy research and development. Academic institutions, research
hospitals, and biotechnology companies often have specialized facilities,
equipment, and expertise that can be shared through collaborations. Access to
advanced infrastructure and facilities expedites the translation of research
findings into clinical applications and reduce barriers to entry for new
players in the market.
Collaborative
partnerships can support the optimization of manufacturing processes and
scale-up efforts for cell and gene therapies. This includes knowledge sharing,
process development, and technology transfer between organizations. By
leveraging each other's expertise and resources, partners can address
manufacturing challenges, improve scalability, and ensure efficient production
of therapies. Collaborative manufacturing efforts enable the timely and
cost-effective delivery of therapies to patients. Collaborative partnerships
enable access to a diverse patient population for clinical trials and
real-world evidence generation. By partnering with healthcare providers,
patient advocacy groups, and patient registries, researchers, the companies can
recruit participants, collect patient data, and engage with the patient
community. Patient-centric collaborations foster awareness, understanding, and
acceptance of cell and gene therapies, driving their growth and adoption.
Growing Demand
for Innovative Treatments
The growing
demand for innovative treatments has a significant influence on the growth of
the cell and gene therapy market in Canada. Cell and gene therapies offer
the potential to address unmet medical needs for patients with conditions that
have limited treatment options. These innovative therapies can provide curative
or disease-modifying solutions for diseases such as cancer, genetic disorders,
and autoimmune conditions. The growing demand for effective treatments for
these diseases has created a market opportunity for cell and gene therapies to
fill the therapeutic gap and improve patient outcomes. Patient advocacy groups
and organizations play a crucial role in driving the demand for innovative
treatments. These groups actively raise awareness about diseases and advocate
for improved treatment options.
As patients and
their families become more informed about the potential benefits of cell and
gene therapies, they are increasingly demanding access to these innovative
treatments. The advocacy efforts of patient groups contribute to shaping
policies, securing funding, and expanding access to cell and gene therapies in
Canada. The demand for innovative treatments is driven by the
potential economic impact and cost-effectiveness of cell and gene therapies.
Although these therapies may initially have high upfront costs, they have the
potential to provide long-term cost savings by reducing the need for chronic
disease management, hospitalizations, and costly interventions. As healthcare
systems recognize the value and cost-effectiveness of these therapies, the
demand for their adoption increases.
Favorable
investment climate
A favorable
investment climate has a significant influence as it attracts increased funding
opportunities for the growth of the cell and gene therapy market in Canada. Venture
capital firms, private equity investors, and other financial institutions are
more likely to invest in the sector when the climate is favorable. This influx
of funding enables companies to advance their research and development efforts,
conduct clinical trials, optimize manufacturing processes, and bring innovative
therapies to market more quickly. A favorable investment
climate attracts top talent and expertise to the cell and gene therapy sector
in Canada. Highly skilled researchers, scientists, clinicians, and industry
professionals are more likely to join companies and research institutions when
there are ample investment opportunities available. The presence of a talented
workforce enhances the research and development capabilities, manufacturing
expertise, and commercialization efforts, contributing to the overall growth of
the market. Favorable investment conditions support market expansion
efforts for Canadian cell and gene therapy companies. Increased investment
capital allows companies to explore new markets, expand their reach, and engage
in international collaborations. International partnerships can bring
additional funding, expertise, and access to global markets, contributing to
the growth and competitiveness of the Canadian cell and gene therapy market. A
favorable investment climate in Canada's cell and gene therapy sector attracts
foreign direct investment (FDI). Foreign investors recognize the potential of
the Canadian market, including the presence of a skilled workforce, robust
research infrastructure, and supportive regulatory environment. FDI brings
additional capital, expertise, and market opportunities, driving the growth of
the market and fostering international collaborations.
Clinical Trials
Propels the Market Growth
Clinical trials
play a crucial role in influencing the growth of the cell and gene therapy
market in Canada. Clinical trials are essential for
evaluating the safety and efficacy of cell and gene therapies. These trials
provide valuable data on the therapeutic benefits, potential side effects, and
optimal dosing regimens. Positive clinical trial outcomes build confidence in
the effectiveness and safety of these therapies, driving their adoption and
commercialization. Safety and efficacy data from clinical trials are required
for regulatory approvals and reimbursement decisions. Clinical trials provide the
necessary data and evidence to support regulatory approvals from Health Canada.
Regulatory approval is a critical milestone for the commercialization of cell
and gene therapies. Positive clinical trial results demonstrating safety and
efficacy increase the likelihood of obtaining regulatory approvals, allowing
therapies to enter the market and reach patients. Clinical trials generate
valuable scientific knowledge and advancements in the field of cell and gene
therapies. They contribute to the understanding of disease mechanisms,
treatment approaches, and patient responses. These insights enable researchers
and companies to refine their therapies, identify new therapeutic targets, and
optimize treatment protocols. The accumulation of scientific knowledge through
clinical trials drives further research and development efforts, fostering
innovation and growth in the market. Clinical trials provide an
opportunity for patients to access innovative therapies before they are widely
available. Participation in clinical trials allows patients to receive
potentially life-changing treatments and contribute to advancing scientific knowledge.
As patients engage in clinical trials, they become advocates and ambassadors
for cell and gene therapies, raising awareness and driving demand for these
treatments. Patient engagement and awareness generated through clinical trials
positively influence the growth of the market.
Recent
Development
- Kymriah (tisagenlecleucel): Kymriah, developed by
Novartis, is a chimeric antigen receptor T-cell (CAR-T) therapy. It was
approved by Health Canada in May 2019 for the treatment of pediatric and young
adult patients up to 25 years old with relapsed or refractory B-cell acute
lymphoblastic leukemia (ALL). Kymriah is an innovative therapy that involves
genetically modifying a patient's T-cells to recognize and attack cancer cells.
- Luxturna (voretigene neparvovec): Luxturna, developed
by Spark Therapeutics (now part of Roche), is a gene therapy used for the
treatment of inherited retinal dystrophy caused by mutations in the RPE65 gene.
It was approved by Health Canada in December 2019. Luxturna delivers a
functional copy of the RPE65 gene to the retinal cells, restoring vision in
patients with this rare genetic disorder.
- Zynteglo (autologous CD34+ cells encoding
βA-T87Q-globin gene): Zynteglo, developed by bluebird bio. It is a gene therapy
for transfusion-dependent β-thalassemia. It was conditionally approved by
Health Canada in April 2021. Zynteglo involves genetically modifying a
patient's own hematopoietic stem cells to produce functional hemoglobin. This
therapy reduces or eliminates the need for blood transfusions in patients with
transfusion-dependent β-thalassemia.
Market Segmentation
Canada cell and
gene therapy market can be segmented by type,
indication, end user, and region. Based on type, Canada cell and gene
therapy market can be divided into Cell Therapy v/s
Gene Therapy. Based on indication, Canada cell and gene therapy market can
be segmented into oncology diseases, cardiovascular diseases, orthopedic
diseases, neurological diseases, and others. Based on end user, Canada cell and
gene therapy market can be segmented into hospitals & clinics, academic
& research institutions, and others. Regionally, Canada Cell and Gene
therapy Market can be categorized into Quebec, Ontario, Alberta, British
Columbia, Saskatchewan & Manitoba, and rest of Canada.
Market Players
Amgen Canada Inc, Kolon TissueGene Inc, Novartis
Pharmaceuticals Canada Inc, Pfizer Canada Inc, Gilead Sciences Inc,
Bristol-Myers Squibb Canada Inc, Merck & Co Inc are some of the leading players
operating in the Canada Cell and Gene Therapy Market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
Type
Indication
End User
Region
|
|
Regional
scope
|
Quebec
Region, Ontario Region, Alberta Region, British Columbia Region, Saskatchewan &
Manitoba Region, Rest of
Canada
|
|
Key
companies profiled
|
Amgen Canada Inc,
Kolon TissueGene Inc, Novartis Pharmaceuticals Canada Inc, Pfizer Canada Inc,
Gilead Sciences Inc, Bristol-Myers Squibb Canada Inc, Merck & Co Inc
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the Canada cell and gene therapy
market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
·
Canada Cell and Gene
Therapy Market,
By Type:
o Cell Therapy
o Gene Therapy
·
Canada Cell and Gene
Therapy Market,
By Indication:
o Direct Oncology Diseases
o Cardiovascular Diseases
o Orthopedic Diseases
o Neurological Diseases
o Others
·
Canada Cell and Gene
Therapy Market,
By End User:
o Hospitals & Clinics
o Academic & Research Institutions
o Others
·
Canada Cell and Gene
Therapy Market, By Region:
o Quebec Region
o Ontario Region
o Alberta Region
o British Columbia Region
o Saskatchewan & Manitoba Region
o Rest of Canada
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present Canada cell and gene therapy market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Canada cell and gene therapy market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]